In the past, biosimilar makers have been able to invalidate some of those patents through a sped-up process called “inter ...

Getting your Trinity Audio player ready... The drugmaker Amgen has sued Colorado’s Prescription Drug Affordability Board for a second time, alleging that the board’s decision last month to set a price ...

Real-world data suggest anti-TNF biosimilars for juvenile idiopathic arthritis offer comparable efficacy and safety to their brand name counterparts. As high-cost originator biologics continue to ...

Humira (adalimumab) is a prescription drug used to treat hidradenitis suppurativa (HS). It helps reduce moderate to severe symptoms of this condition. Humira is also available in biosimilar forms.

The approval of the interchangeable designation was supported by data from a randomized, double-blind phase 4 trial (ClinicalTrials.gov Identifier: NCT05510063) that assessed the pharmacokinetics, ...

Credit: Celltrion. Yuflyma, a tumor necrosis factor blocker, was approved in May 2023 as a biosimilar to Humira. Similar PK, efficacy, safety, and immunogenicity data were observed between the ...

Medicare was authorized to negotiate prices it will pay for Part D drugs. Enbrel, the original version of etanercept, was among the first 10 drugs to be subject to negotiations. The negotiated price ...

Blue Shield of California has cut the price it will pay for a biosimilar of the drug Humira. Blue Shield will purchase the medicine used to treat certain autoimmune and inflammatory diseases, such as ...

Humira (adalimumab) treats certain types of arthritis and inflammatory diseases. This prescription drug is a liquid for injection under your skin. Humira may not be safe to receive while pregnant but ...

UnitedHealth Group Inc. (NYSE:UNH) reportedly announced on Tuesday that it will remove AbbVie Inc.’s (NYSE:ABBV) blockbuster drug Humira from some of its preferred reimbursement lists starting January ...